The
India Expo Mart brings the event closer to Indian regulatory and legislative hub and will encourage international audiences
Amsterdam, 11 June 2018:
CPhI
& P-MEC India (December 10-14, 2018)
– organised by UBM – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the
India
Expo Mart, New Delhi. The new venue will see the exhibition now hosted
in a single venue, bringing it closer to the Indian regulatory and
legislative capital.
New Delhi is also the country’s main international transport hub and
will encourage an increased international attendance. In total, more
than 50,000 people from 122 countries are expected, along with nearly
1,500 exhibitors.
CPhI & P-MEC India comes with the backing of the Delhi-based
Pharmaceuticals
Export Promotion Council of India (Pharmexcil) – the organisation
behind key Government international strategies such as ‘Made in India’.
Mr. Yogesh Mudras, Managing Director, UBM India
commented
“the shift to the Delhi-NCR region, in close geographical proximity to
the policy makers, consulates and government bodies will enhance our
community
building efforts, as well as the creation of a robust pharma
eco-system.”
Government investment plans
– including a US$ 640 million venture capital fund to boost drug discovery
and strengthen pharmaceutical infrastructure – and the ‘Pharma Vision 2020’
initiative are creating new benefits for government engagement with industry.
UBM
cited rising international interest in the event as a key factor in the
move, with numbers of both international and domestic exhibitors
requiring a far bigger venue – and on a single site.
Mr
Mudras
added “I
am delighted that
CPhI & P-MEC India
will
be held this year at India Expo Mart, Greater Noida – it’s the flagship
platform for the Indian pharma industry and one of the world’s leading
Pharmaceutical
networking events. It’s also a major international hub, with India’s
largest airport, and this venue change is looking ahead to future
audience needs.
The venue change is also seen as a boost to domestically focused markets by bringing a wider remit of attendees and greater
access to national regulatory pathways. The country registers the second largest Abbreviated New Drug Applications (ANDAs) globally and is the world’s
leader in Drug Master Files (DMFs) applications, so access to regulatory expertise has never been greater.
The 2018 edition will also feature
India Pharma Week (returning for a third year), with 10
unique events and activities spanning the Indian Capital. These include dynamic engagements such as the
Pharma Leader’s Golf Pre-Connect Congress, Plant Visits, Women in Pharma – Power Breakfast, India Pharma Awards, Networking
Evening, and a closed-door CEO Roundtable, amongst others.
The
ultimate goal of all these intertwined events is to help nurture a
complete pharma ecosystem in India and better enable
networking with the country’s corridors of power. In fact, the recent
CPhI Global Pharma Index showed India represents global pharma’s second
fastest growing market and praised the Delhi based regulator, the CDSCO (Central
Drugs Standard Control Organization) for its
efforts in introducing a
certification
programme and initiatives for increased compliance. Impressively, 52%
of international respondents believed the CDSCO is moving toward
comparability with the regulatory
standards of the EMA and FDA.
- ENDS-
Notes to editors
About CPhI
CPhI
drives growth and innovation at every step of the global pharmaceutical
supply chain from drug discovery to finished dosage. Through
exhibitions,
conferences and online communities, CPhI brings together more than
100,000 pharmaceutical professionals each year to network, identify
business opportunities and expand the global market. CPhI hosts events
in Europe, North America, Korea, China, India, Japan,
Southeast Asia and the Middle East, and co-locates with ICSE for
contract services, P-MEC for machinery, equipment & technology, FDF
for finished dosage formulations, InnoPack for pharmaceutical packaging
and BioPh for biopharma. CPhI provides an online buyer
& supplier directory at CPhI-Online.com.
For more information visit:
www.cphi.com
The
UBM annual schedule of Pharmaceutical events includes: CPhI and P-MEC
China (20-22 June, 2018 at SNIEC – Shanghai, China); CPhI Korea
(28-30 August 2018, COEX, Seoul, Korea); CPhI Middle East & Africa
(3-5 September, 2018 at the ADNEC
– Abu Dhabi, United Arab Emirates). BioLIVE (9-11, October, 2018 in
Madrid); CPhI, ICSE, P-MEC, FDF and InnoPack
Worldwide (9-11 October, 2018 at the IFEMA, Feria de Madrid – Madrid,
Spain); CPhI & P-MEC India (3–6 December 2018 at the BEC and BKC
Exhibition and Convention Centres – Mumbai, India); Pharmapack Europe
(6-7 February, 2019 at the Paris Expo, Porte de Versailles
– Paris, France); CPhI, P-MEC, ICSE, FDF, Labworld and Innopack South
East Asia (18-20 March, 2019 – Bangkok, Thailand). CPhI, ICSE, FDF and
InnoPack North America (30 April - 2 May, 2019 at the Pennsylvania
Convention Center – Philadelphia, USA)
About UBM
UBM
is the largest pure-play B2B Events organizer in the world. Our 3,750+
people, based in more than 20 countries, serve more than 50
different sectors. Our deep knowledge and passion for these sectors
allow us to create valuable experiences which enable our customers to
succeed. Please visit www.ubm.com for
the latest news and information about UBM. CPhI, ICSE, P-MEC, BioPh and InnoPack Japan (18-20 April, 2018 at the Big Sight Exhibition Centre – Tokyo, Japan); CPhI, ICSE,
FDF and InnoPack North America (24-26 April, 2018 at the Pennsylvania Convention Center – Philadelphia, USA)
About UBM India:
UBM
India is India's leading exhibition organizer that provides the
industry with platforms that bring together buyers and sellers from
around the world,
through a portfolio of exhibitions, content led conferences &
seminars. UBM India hosts over 25 large scale exhibitions and 40
conferences across the country every year; thereby enabling trade across
multiple industry verticals. A UBM Asia Company, UBM India
has offices across Mumbai, New Delhi, Bangalore and Chennai. UBM Asia
is owned by UBM plc which is listed on the London Stock Exchange. UBM
Asia is the leading exhibition organizer in Asia and the biggest
commercial organizer in mainland China, India and Malaysia.
For further details, please visit ubmindia.in.
For media enquiries, please contact:
Alex Heeley or Alex Allsop
De Facto Communications
T: +44 (0) 203 735 8168
E:
a.heeley@defacto.com /
a.allsop@defacto.com